Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure Of Hepatitis C Helicase Enzyme; Report In Structure

Cambridge, MA, January 15, 1998 -- Researchers from Vertex Pharmaceuticals Incorporated have solved the three-dimensional atomic structure of the hepatitis C virus NS3 helicase, an enzyme that plays a key role in viral replication. The achievement is described in a paper, "Hepatitis C Virus NS3 RNA Helicase Domain with a Bound Oligonucleotide: The Crystal Structure Provides Insights into the Mode of Unwinding," published in the January 15, 1998 issue of the journal Structure. The publication follows the presentation of the helicase structure at the Second International Conference on Therapies for Viral Hepatitis in Kona, Hawaii, in December 1997. Vertex is using the structural information to design hepatitis C helicase inhibitors as new antiviral drugs to treat hepatitis C virus (HCV) infection.

"This paper presents for the first time detailed information on the critical interaction between the hepatitis C helicase and viral RNA," said Dr. Joseph L. Kim, Vertex crystallographer and an author of the Structure paper. "The nucleic acid binding site of the helicase enzyme, as well as the previously described nucleoside triphosphate (NTP) binding site, are attractive targets for disrupting this interaction. These two targets, which comprise the active sites of the helicase enzyme, are a focus of our ongoing drug design efforts."

Helicases are enzymes distinguished by their ability to unwind regions of double-stranded RNA or DNA, in preparation for replication or transcription of genetic information. In the case of hepatitis C, the NS3 helicase functions to unwind double-stranded viral RNA complexes. The resulting RNA strands then serve as templates for the synthesis of more RNA or for translation into protein. Alternately, the new RNA may be packaged into new virus particles, which are released from cells to propagate infection.

Vertex scientists determined the three-dimensional structure of h

Contact: Michael Partridge
(617) 577-6108
Vertex Pharmaceuticals

Page: 1 2 3 4

Related biology news :

1. Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertexs Investigational IMPDH Inhibitor VX-497
2. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
3. Vertex Researchers Report Three-Dimensional Atomic Structure Of JNK3 Enzyme; Report In Structure
4. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
5. Warren Pharmaceuticals publishes results of preclinical evaluation
6. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
7. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
8. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
9. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
10. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:

(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
Cached News: